ReviewMicroorganisms2020
Is Gut Microbiota Dysbiosis a Predictor of Increased Susceptibility to Poor Outcome of COVID-19 Patients? An Update.
Review in Microorganisms, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 49 citations in OpenAlex.
- Small Intestinal Bacterial Overgrowth (SIBO) - Prevention and Therapeutic Role of Nutrition, Prebiotics, Probiotics, and Prokinetics.Current pharmaceutical design · 2025Review
- Unveiling the role of the upper respiratory tract microbiome in susceptibility and severity to COVID-19.Frontiers in cellular and infection microbiology · 2025Article
- Article
- Molecular Accounting and Profiling of Human Respiratory Microbial Communities: Toward Precision Medicine by Targeting the Respiratory Microbiome for Disease Diagnosis and Treatment.International journal of molecular sciences · 2023Review
- Serum biomarkers for nutritional status as predictors in COVID-19 patients before and after vaccination.Journal of functional foods · 2023Article
- Changes of gut microbiota under different nutritional methods in elderly patients with severe COVID-19 and their relationship with prognosis.Frontiers in immunology · 2023Article
- Coinfection with influenza virus and non-typeableFrontiers in microbiology · 2023Article
- The impact of infection with COVID-19 on the respiratory microbiome: A narrative review.Virulence · 2022Review
- Downregulation of ACE, AGTR1, and ACE2 genes mediating SARS-CoV-2 pathogenesis by gut microbiota members and their postbiotics on Caco-2 cells.Microbial pathogenesis · 2022Article
- Gut bacteria, bacteriophages, and probiotics: Tripartite mutualism to quench the SARS-CoV2 storm.Microbial pathogenesis · 2022Review
- Gastrointestinal parasites of six large mammals in the Wasgomuwa National Park, Sri Lanka.International journal for parasitology. Parasites and wildlife · 2022Article
- Nasopharyngeal Microbiota as an early severity biomarker in COVID-19 hospitalised patients.The Journal of infection · 2022Article
- The Continuing Emergence ofJournal of fungi (Basel, Switzerland) · 2022Article
- COVID-19 as an infectome paradigm of autoimmunity.The Journal of allergy and clinical immunology · 2022Article
- Gut microbiota composition in COVID-19 hospitalized patients with mild or severe symptoms.Frontiers in microbiology · 2022Article
- The intestinal microbiota and improving the efficacy of COVID-19 vaccinations.Journal of functional foods · 2021Review
- Increased LPS levels coexist with systemic inflammation and result in monocyte activation in severe COVID-19 patients.International immunopharmacology · 2021Article
- Dysbiosis and structural disruption of the respiratory microbiota in COVID-19 patients with severe and fatal outcomes.Scientific reports · 2021Article
- Sunlight Exposure and Phototherapy: Perspectives for Healthy Aging in an Era of COVID-19.International journal of environmental research and public health · 2021Review
- Response.Chest · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The scientific knowledge already attained regarding the way severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects human cells and the clinical manifestations and consequences for Coronavirus Disease 2019 (COVID-19) patients, especially the most severe cases, brought gut microbiota into the discussion. It has been suggested that intestinal microflora composition plays a role in this disease because of the following: (i) its relevance to an efficient immune system response; (ii) the fact that 5-10% of the patients present gastrointestinal symptoms; and (iii) because it is modulated by intestinal angiotensin-converting enzyme 2 (ACE2) (which is the virus receptor). In addition, it is known that the most severely affected patients (those who stay longer in hospital, who require intensive care, and who eventually die) are older people with pre-existing cardiovascular, metabolic, renal, and pulmonary diseases, the same people in which the prevalence of gut microflora dysbiosis is higher. The COVID-19 patients presenting poor outcomes are also those in which the immune system's hyperresponsiveness and a severe inflammatory condition (collectively referred as "cytokine storm") are particularly evident, and have been associated with impaired microbiota phenotype. In this article, we present the evidence existing thus far that may suggest an association between intestinal microbiota composition and the susceptibility of some patients to progress to severe stages of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.